19 unknown, 7 not yet recruiting, 7 recruiting, 4 active not recruiting. 27 Phase 2, 10 Phase 3, 8 Phase 1, 1 Not applicable.
Follow HLX10: new trials by email Literature Review of HLX10 trials Research Report on HLX10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer Short-course radiotherapy, Long-course radiotherapy, Capecitabine - Rectal Cancer, Total Neoadjuvant Therapy | Phase 3 | Recruiting | Tao Zhang | 444 | 2026-05-15 | 2026-05-13 |
| Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma HLX10, SOX Chemotherapy - ctDNA, Gastric Cancer | Phase 2 | Not yet recruiting | Fudan University | 32 | 2026-04-01 | 2026-04-02 |
| Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC HLX10, Chemotherapy, Nimotuzumab - Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 46 | 2026-03-12 | 2026-03-11 |
| A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer HLX07, HLX07 placebo, Serplulimab - Squamous NSCLC | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 720 | 2026-03-01 | 2026-01-06 |
| A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC HLX43 DOSE 1, HLX43 DOSE 2, Serplulimab - Non Small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Henlius Biotech | 60 | 2026-01-20 | 2026-06-04 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. HLX53 (1000mg), HLX53 (2000mg), HLX10 - Carcinoma, Hepatocellular | Phase 2 | Recruiting | Shanghai Henlius Biotech | 117 | 2024-08-05 | 2024-12-18 |
| Combining Chemoradiotherapy With Sintilimab in First-Line ICC radiotherapy, gemcitabine + cisplatin, slulimumab - ICC | Not yet recruiting | Shanghai Zhongshan Hospital | 19 | 2024-07-01 | 2024-06-07 | |
| Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer Serplulimab, Capecitabine, Oxaliplatin - Colon Cancer | Phase 2 | Recruiting | Ruijin Hospital | 56 | 2024-05-01 | 2025-09-24 |
| PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer Serplulimab, mFOLFOX6 - Metastatic Colon Cancer | Not applicable | Unknown | Henan Cancer Hospital | 23 | 2024-04-01 | 2024-03-28 |
| A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors HLX43, HLX10 - Advanced/Metastatic Malignant Solid Tumors | Phase 1 | Enrolling by invitation | Shanghai Henlius Biotech | 367 | 2023-11-24 | 2026-10-13 |
| Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC Serplulimab, Chest Radiation - Extensive Stage Lung Small Cell Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 100 | 2023-10-18 | 2024-04-05 |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients HLX26, Serplulimab, Chemotherapy drug - NSCLC Stage IV | Phase 2 | Active not recruiting | Shanghai Henlius Biotech | 132 | 2023-07-10 | 2025-08-06 |
| Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC HLX26, HLX10 - Colorectal Cancer Metastatic | Phase 2 | Terminated | Shanghai Henlius Biotech | 2 | 2023-06-15 | 2024-10-15 |
| Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure Serplulimab, Bevacizumab Biosimilar HLX04, Pemetrexed - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 46 | 2023-05-08 | 2024-03-28 |
| Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma Fruquintinib combined with Serplulimab - Non-clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | RenJi Hospital | 40 | 2023-05-01 | 2026-09-16 |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer HLX07, HLX10, carboplatin and etoposide - Small-cell Lung Cancer | Phase 2 | Unknown | Shanghai Henlius Biotech | 20 | 2023-03-29 | 2022-05-04 |
| Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer Serplulimab - Cervical Cancer | Unknown | Shandong University | 118 | 2023-03-09 | 2023-06-01 |
Showing 20 of 43. Sign in to see all of them.
Small Cell Lung Carcinoma (4) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Meningioma (2) · Neurofibromatosis 2 (2) · Neuroma, Acoustic (2) · Rectal Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Colorectal Neoplasms (1) · Ependymoma (1) · Esophageal Squamous Cell Carcinoma (1)
Shanghai Henlius Biotech (23) · Beijing Tiantan Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Henan Cancer Hospital (2) · Henlix, Inc (2) · RenJi Hospital (2) · Fudan University (1) · Ruijin Hospital (1) · Second Affiliated Hospital of Soochow University (1) · Shandong University (1) · Shanghai Zhongshan Hospital (1) · Sichuan University (1) · Tao Zhang (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Zhejiang Cancer Hospital (1)
China (32) · Poland (3) · United States (3) · Georgia (2) · Japan (2) · Russia (2) · Taiwan (2) · Turkey (Türkiye) (2) · Ukraine (2) · Austria (1) · Czechia (1) · Germany (1) · Greece (1) · Hungary (1) · Latvia (1)
Beihua Kong, MD.PhD. (1) · Chang Chen, Dr (1) · Cheng-Yuan Peng, MD, PhD (1) · Chia-Yen Dai, MD, PhD (1) · Gi-Ming Lai, MD (1) · Guangyuan Hu (1) · Guochun Cao (1) · Huichuan Sun, Dr (1) · Jia Fan (1) · Jia-Horng Kao, MD, PhD (1) · Jie Wang, Dr. (1) · Jinming Yu, MD (1) · Meiyu Fang (1) · Nan Bi, Doctor (1) · Peng Junjie (1)
PMID 40932107, PMID 36166026, PMID 36261583, PMID 36685541, PMID 38181795, PMID 38194016, PMID 38870931, PMID 40398957, PMID 41538111, PMID 42225112, PMID 42240984